The ASH annual meeting virtual platform will open on Wednesday, December 7, 2022, to all attendees. Most sessions offered at the in-person meeting will be broadcast simultaneously on the virtual platform. The platform will also include on-demand (recorded) sessions as well as access to networkin...
12月10日-12月13日,麓鹏制药LP-118最新的三项临床前研究数据亮相第64届美国血液学会年会(64th ASH Annual Meeting)。LP-118是麓鹏制药自主研发的新一代BCL-2抑制剂,同时靶向BCL-2和BCL-xL,并可以克服BCL-2突变导致的对第一代抑制剂维奈托克的耐药。该项目目前在中美同时开展临床研究。 三项研究通过原代恶性肿瘤...
The ASH annual meeting virtual platform will open on Wednesday, December 7, 2022, to all attendees. Most sessions offered at the in-person meeting will be broadcast simultaneously on the virtual platform. The platform will also include on-demand (recorded) sessions as well as access to networkin...
JW Therapeutics Presents Latest Clinical Data on Carteyva® in Follicular Lymphoma and Mantle Cell Lymphoma at the 64th ASH Annual Meeting SHANGHAI, CHINA, December 12, 2022- JW Therapeutics (HKEX: 2126), an independent and...
Create a free account to read the full article Gain access to the world’s leading investment community. Already registered? Sign in Create Free Account By creating an account using any of the options above, you agree to the Terms of Use & Privacy Policy or Continue with Goo...
中国上海,2022年12月12日– 药明巨诺(港交所代码:2126),一家独立的、专注于研发、生产及商业化细胞免疫治疗产品的创新型生物科技公司,在第64届美国血液学会(ASH)年会上公布了倍诺达®(瑞基奥仑赛注射液)分别在中国成人复发/难治性滤泡...